Zonisamide

Drug Profile

Zonisamide

Alternative Names: AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran

Latest Information Update: 26 Jun 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Concordia Pharmaceuticals; Dainippon Sumitomo Pharma; Eisai Co Ltd; Sumitomo Dainippon Pharma
  • Class Antiepileptic drugs; Isoxazoles
  • Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Parkinson's disease
  • Phase III Lewy body disease
  • Discontinued Cerebral ischaemia; Manic episodes; Migraine; Neuropathic pain; Obesity

Most Recent Events

  • 22 Jun 2017 Eisai licenses zonisamide to Ewopharma for commercialisation in Hungary
  • 06 Apr 2017 Sumitomo Dainippon Pharma intends to submit a supplemental New Drug Application in Japan for Parkinsonism in Dementia with Lewy body disease in 2017
  • 06 Apr 2017 Topline efficacy and adverse events data from a pivotal phase III trial in Parkinsonism of Dementia with Lewy body disease released by Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top